Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经后松症药物。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经后松症药物。
声明:以上例、词性分类均由互联网
动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性受体调节剂,为预防绝经后骨质疏松症药物。
声明:以上例、词性分类均由互联网资源自动生成,部分未经过人工审
,
达内容亦不代
本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预后骨质疏松症药物。
声明:以上例、词性分类均由互联网资源自动
,
分未
过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激调节剂,为预防绝经后骨质疏松症药物。
声明:以上例、词性分类均由互联网资源自动生成,部分未经过人
,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
芬是一种选择性雌激素受体调节剂,为预防绝经后骨质疏松症药物。
声明:以上例、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表
软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经后骨症药物。
声明:以上例、词性分类均由互联
自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择雌激素受体调节剂,为预防绝经后骨质疏松症药物。
声明:以、词
分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选激素受体调节剂,为预防绝经后骨质疏松症药物。
声明:以上例、词
分类均由互联网资源自动生成,部分未经过人工审核,其
容亦不代
本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是择性雌激素受体调节剂,为预防绝经后骨质疏松症药物。
声明:以上例、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内
代表本软件的观点;若发现问题,欢迎向我们指正。